ClinicalTrials.gg

Program

iptacopan

Also written as “Iptacopan”, “LNP023” and “Iptacopan (LNP023)”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Glomerulonephritis, IGA · Atypical Hemolytic Uremic Syndrome · Proteinuria · Macular Degeneration, led by Novartis.

Furthest: phase 3, since May 3, 201925 company-led studies, 12 open or runningNext primary completion: Dec 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis2512 open or runningphase 3since May 3, 2019Nov 30, 2017Dec 30, 2026phase 2 · NCT06388941

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Nov 30, 2017.

  1. Mar 23, 20212 phase 3 studiesNCT04817618, NCT04820530
  2. May 7, 2021Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT04889430 · 34 enrolled · United States, Brazil, China and more
  3. Sep 28, 2021Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT05086744 · 19 enrolled · United States, Germany, Italy and more
  4. Oct 13, 2021Phase 1 study in Hepatic ImpairmentNCT05078580 · 38 enrolled · United States
  5. Jan 28, 2022Phase 2 study in Macular DegenerationNCT05230537 · 168 enrolled · United States, China, Puerto Rico and more
  6. Nov 18, 2022Phase 3 study in Hemoglobinuria, ParoxysmalNCT05630001 · 52 enrolled · United States, France, Germany and more
  7. Feb 23, 2023Phase 3 study in ProteinuriaNCT05755386 · 106 planned · United States, Argentina, Brazil and more
  8. Mar 21, 2023Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT05795140 · 65 planned · Brazil, China, Czechia and more
  9. Jun 29, 2023Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT05935215 · 50 planned · China, France, Germany and more
  10. Feb 12, 2024Phase 3 study in Myasthenia GravisNCT06517758 · 146 enrolled · United States, Argentina, Australia and more
  11. Apr 17, 2024Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06388941 · 84 enrolled · United States, Argentina, Australia and more
  12. Jan 21, 2025Phase 2 study in Glomerulonephritis, IGANCT06797518 · 20 planned · United States, Argentina, Israel and more
  13. Mar 31, 2025Phase 3 study in Hemoglobinuria, ParoxysmalNCT06934967 · 12 planned · United States, Brazil, Colombia and more
  14. May 20, 2025Phase 3 study in Glomerulonephritis, IGANCT06994845 · 31 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 30, 2026Primary completion: phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06388941
  2. Jan 29, 2027Primary completion: phase 3 study in ProteinuriaNCT04817618
  3. Apr 30, 2027Primary completion: phase 3 study in Myasthenia GravisNCT06517758
  4. Oct 18, 2027Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT04747613

TargetBeta

CFB →read by rule
“Complement factor B inhibitor; Complement factor B inhibitor”ChEMBL 37, by rule

Other programs on CFB

ProgramCompanyFurthest phaseStudies
HRS-5965Jiangsu HengRui Medicinephase 314
NTQ5082ruleSino Biopharmaceuticalphase 36
FXS6837Fosun Pharmaphase 34
sefaxersenHoffmann-La Rochephase 31
HS-10542Hansoh Pharmaceutical Groupphase 23
FWY003Novartisphase 21
SAR446597Sanofiphase 21

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06994845Glomerulonephritis, IGA · United States, Argentina, Australia and more3RecruitingJun 28, 203031
NCT06934967Hemoglobinuria, Paroxysmal · United States, Brazil, Colombia and more3RecruitingOct 14, 203112
NCT06797518Glomerulonephritis, IGA · United States, Argentina, Israel and more2RecruitingNov 27, 202720
NCT06388941Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · United States, Argentina, Australia and more2Active, not recruitingDec 30, 202684
NCT06517758Myasthenia Gravis · United States, Argentina, Australia and more3Active, not recruitingApr 30, 2027146
NCT05935215Atypical Hemolytic Uremic Syndrome · China, France, Germany and more3RecruitingJul 21, 202850
NCT05795140Atypical Hemolytic Uremic Syndrome · Brazil, China, Czechia and more3RecruitingJul 16, 203265
NCT05755386Proteinuria · United States, Argentina, Brazil and more3RecruitingOct 27, 2028106
NCT05630001Hemoglobinuria, Paroxysmal · United States, France, Germany and more3CompletedOct 17, 202452
NCT05230537Macular Degeneration · United States, China, Puerto Rico and more2CompletedAug 19, 2026168
NCT05078580Hepatic Impairment · United States1CompletedJun 20, 202238
NCT05086744Purpura, Thrombocytopenic, Idiopathic · United States, Germany, Italy and more2TerminatedSep 20, 202319
NCT04889430Atypical Hemolytic Uremic Syndrome · United States, Brazil, China and more3CompletedApr 11, 202634
NCT04820530Hemoglobinuria, Paroxysmal · China, France, Germany and more3CompletedNov 2, 202240
NCT04817618Proteinuria · United States, Argentina, Belgium and more3RecruitingJan 29, 202798
NCT04747613Hemoglobinuria, Paroxysmal · United States, Brazil, China and more3Active, not recruitingOct 18, 2027208
NCT04557462Glomerulonephritis, IGA · United States, Argentina, Australia and more3RecruitingDec 4, 2030540
NCT04578834Glomerulonephritis, IGA · United States, Argentina, Australia and more3CompletedSep 19, 2025517
NCT04558918Hemoglobinuria, Paroxysmal · United States, Brazil, Czechia and more3CompletedSep 26, 202297
NCT04154787Glomerulonephritis, Membranous · Argentina, China, Czechia and more2TerminatedJan 20, 202337
NCT03955445Glomerulonephritis, Membranoproliferative · United States, Argentina, Brazil and more3RecruitingMay 30, 2036225
NCT03896152Hemoglobinuria, Paroxysmal · Korea, Republic of, Malaysia, Singapore and more2CompletedApr 7, 202013
NCT03832114Glomerulonephritis · United States, France, Germany and more2CompletedApr 23, 202127
NCT03439839Hemoglobinuria, Paroxysmal · France, Germany, Italy2CompletedApr 22, 202016
NCT03373461Glomerulonephritis, IGA · Argentina, Australia, Belgium and more2CompletedDec 29, 2020112

How it is read

Names in the registry

  • “Iptacopan”, 12 entries
  • “LNP023”, 9 entries
  • “iptacopan”, 4 entries
  • “Iptacopan (LNP023)”, 2 entries
  • “Iptcaopan 200 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.